A proposed clinical algorithm for using carcinogenic human papillomavirus (HPV) testing as the primary screening test and HPV genotyping to triage carcinogenic HPV-positive results and monitor viral persistence as a risk factor for cervical precancer and cancer. If the molecular HPV test used for screening (e.g., Hybrid Capture 2 (Digene Corporation, Gaithersburg, Maryland)) does not provide information on the individual HPV genotype(s) present, only on whether a woman is or is not positive for carcinogenic HPV, a second test would be necessary to determine which HPV genotype(s) are present. Cytologic analysis may be a useful adjunct for women whose screening history is unknown, with women having cytologically detected high-grade squamous intraepithelial lesions (HSIL) being referred to colposcopy immediately. Depending on the exact format of the HPV testing (full or partial HPV genotyping), the most robust use of HPV genotyping, and the associated risks of cervical intraepithelial neoplasia grade 3 or cervical cancer (≥CIN3), women who repeatedly test positive for the other carcinogenic HPV genotypes (individually or in aggregate) may need increased surveillance or colposcopy (31). Following a carcinogenic HPV-negative test, women may be rescreened at an extended interval of 3 or more years, depending on the acceptable risk of ≥CIN3 (and, more specifically, the reassurance against cancer), which may depend on the previous test results.